Medicalgorithmics to Provide AI Solutions for Cardiac Diagnostics to German Company
Medicalgorithmics, a global medtech company, is proud to announce that it has entered into agreement with a German medical equipment provider livetec Ingenieurbüro GmbH to deliver advanced artificial intelligence (AI) solutions for cardiac diagnostics. The partnership anticipates a seamless integration of Medicalgorithmics’ software with livetec’s ECG monitoring devices. This marks another integration of Medicalgorithmics’ artificial intelligence-based software […]
Medicalgorithmics Expands Reach with New Contract with U.S.Independent Diagnostic Testing Facility (IDTF)
Medicalgorithmics, a leading global medtech company, is proud to announce its partnership with a prominent Independent Diagnostic Testing Facility (IDTF) located in the United States. This alliance underscores Medicalgorithmics’ unwavering dedication to elevating the field of cardiology through its state-of-the-art technological solutions. The agreement facilitates the integration of Medicalgorithmics’ AI-driven software platform into the IDTF’s cardiac […]
Medicalgorithmics Explores Entering Sleep Monitoring Market
Medicalgorithmics has signed a letter of intent with Aidmed, a medical technology company focused on sleep monitoring software and medical devices. The collaboration aims to explore the potential commercialization and further development of Aidmed’s solutions. By forging partnership with Aidmed, Medicalgorithmics can expand into a new sleep monitoring market.
AI will assist in early detection of cardiac arrhythmias
An artificial intelligence (AI) system developed by Medicalgorithmics is capable of diagnosing the risk of a dangerous type of cardiac arrhythmia known as ventricular tachycardia before the onset of clinical symptoms, according to a publication by the scientific team at Medicalgorithmics in the renowned American cardiology journal, Heart Rhythm O2.
“Puls Biznesu” on Medicalgorithmics’ New Strategy
“Puls Biznesu,” the leading business newspaper in Poland, reports on the new development strategy of Medicalgorithmics. The newspaper underscores that the company’s key objective until 2026 is to transform its business model from a provider of the closed PocketECG ecosystem into a company offering cutting-edge AI-based solutionsfor cardiac disease diagnostics.
Medicalgorithmics Unveils New Growth Strategy through 2026
Medicalgorithmics has adopted a new growth strategy for 2023-2026 to strengthen its position as a global provider of non-invasive cardiac diagnostic technology. The company will focus on commercializing proprietary software for medical data analysis, AI/ML algorithms, and integrating software with third-party devices.
Medicalgorithmics at the “Progressive Investor Day” Conference
On June 20th (Tuesday), representatives of Medicalgorithmics will participate in the investor conference titled “Progressive Investor Day,” organized in Warsaw by InnerValue and the Warsaw Stock Exchange (GPW).
Investor Webinar with the Management of Medicalgorithmics
On June 21st at 11:00 AM, an investor webinar will take place featuring representatives of the Management Board of Medicalgorithmics.
Medicalgorithmics Reveals Development Plans in Exclusive Strefa Inwestorów Interview
An exclusive interview with Maciej Gamrot and Przemysław Tadla, members of the management board at Medicalgorithmics, has been featured in “Strefa Inwestorów” – a prominent Polish financial medium dedicated to companies listed on the Warsaw Stock Exchange. The interview provides valuable insights into the company’s current operations and its growth plans in the years ahead.
Medicalgorithmics and California Based DMS-Service Join Forcesfor Software Integration and Development
Medicalgorithmics S.A., a global leader in healthcare technology, and dms-service llc, a prominent provider of Holter Monitoring devices, are delighted to announce their collaboration on a software integration. This joint initiative aims to integrate the dms-service llc monitoring hardware with the cutting-edge Medicalgorithmics software platform, unlocking the potential for AI-powered algorithms and predictive analytics. The result will be a world-class combination product offering that enhances the quality, efficiency, and affordability of cardiac monitoring.
Medicalgorithmics SA Signs Letter of Intent with leading North American Health Monitoring Company to Integrate AI-Powered Software Platform with Wearable Biosensors
Warsaw, Poland – Medicalgorithmics, a global healthcare technology company, is pleased to announce signing of a letter of intent with a leading US-based health monitoring company which offers its monitoring services across North America (the name of the partner will be released as soon as it is allowed by the current contractual obligations of the new partner). This collaboration aims to integrate Medicalgorithmics’ cutting-edge AI-powered software with the company’s wearable biosensors, resulting in enhanced health monitoring capabilities, and it is part of the new US business strategy of Medicalgorithmics introduced at the point of investment by BioFund in Q4, 2022
Kardiolytics’ VCAST technology receives new U.S. patent for autonomous segmentation using artificial intelligence for vascular disease diagnosis
Kardiolytics Inc., a subsidiary of Medicalgorithmics S.A., a company listed on the Warsaw Stock Exchange, has announced that it has been granted a new U.S. patent, Patent No. 11626211, for its VCAST technology used to diagnose vascular diseases. The patent concerns an autonomous method for modelling blood vessels and blood flow using a CT angiography scan.